Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | STS | P08842 | 1/20 | 0.44 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.42 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2683675 | 1.00 | ALOX5 (0.48) | ALOX5GPR119ALDH1A1LMNAMAPT | |
| SCHEMBL10167920 | 0.92 | GPR119 (0.47) | GPR119STSPRMT5WDR77TGFBR1 | |
| SCHEMBL6364180 | 0.89 | ALDH1A1 (0.54) | GPR119ALDH1A1LMNAMAPTSTS | |
| SCHEMBL3129522 | 0.89 | ALDH1A1 (0.54) | GPR119ALDH1A1LMNAMAPTSTS | |
| SCHEMBL3127065 | 0.83 | ALDH1A1 (0.52) | GPR119ALDH1A1LMNAMAPTSTS | |
| SCHEMBL13984238 | 0.82 | ALOX5 (0.48) | ALOX5ALDH1A1LMNAMAPTFKBP1A | |
| SCHEMBL26091331 | 0.82 | ALDH1A1 (0.59) | GPR119ALDH1A1LMNAMAPTSTS | |
| SCHEMBL1031264 | 0.82 | USP30 (0.52) | GPR119ALDH1A1LMNAMAPT | |
| SCHEMBL8247003 | 0.82 | USP30 (0.52) | GPR119ALDH1A1LMNAMAPT | |
| SCHEMBL28059322 | 0.82 | USP30 (0.52) | GPR119ALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2635562-B1 | PYRROLIDINE DERIVATIVES USED AS CATHEPSIN INHIBITORS | HOFFMANN LA ROCHE (CH) | 2014-09-03 | — | — | EP | disclosed |
| EP-2635562-A1 | PYRROLIDINE DERIVATIVES USED AS CATHEPSIN INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-09-11 | — | — | EP | disclosed |
| US-8524710-B2 | Pyrrolidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524710-B2 | Pyrrolidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-09-03 | — | — | US | disclosed |
| WO-2012059507-A1 | PYRROLIDINE DERIVATIVES USED AS CATHEPSIN INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-05-10 | — | — | WO | disclosed |
| US-20120115843-A1 | NOVEL PYRROLIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2012-05-10 | — | — | US | disclosed |
| US-20120115843-A1 | NOVEL PYRROLIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115843-A1 | NOVEL PYRROLIDINE DERIVATIVES | CTSD, CTSV, CTSS | ALOX5 3196/4885GPR119 3167/4885ALDH1A1 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.